NCCN Guidelines Now Recommend Naxitamab for High-Risk Neuroblastoma
- OPACC
- Jul 17
- 1 min read
The National Comprehensive Cancer Network (NCCN) has updated its guidelines to include the category 2A recommendation of a naxitamab-gqgk (Danyelza)-based regimen for adult and pediatric patients with high-risk neuroblastoma.
Comments